A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
NCT05652686
This study is recruiting at 15 US sites in 12 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Small Cell Lung Cancer (SCLC)
- Large Cell Neuroendocrine Cancer (LCNEC)
- Neuroendocrine Prostate Cancer (NEPC)
- Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
- Neuroendocrine Carcinomas (NEC)
- Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Phanes Therapeutics
- Last updated on ClinicalTrials.gov
- July 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) · Duarte, CA
- USC Norris Comprehensive Cancer Center · Los Angeles, CA
Colorado · 1
- Sarah Cannon Research Institute at HealthONE · Denver, CO
Connecticut · 1
- Yale University Cancer Center · New Haven, CT
Maryland · 1
- Sidney Kimmel Comprehensive Cancer Center at John Hopkins · Baltimore, MD
Massachusetts · 2
- Dana-Farber Cancer Institute · Boston, MA
- Massachusetts General Hospital · Boston, MA
Missouri · 1
- Washington University School of Medicine (Siteman Cancer Center) · St Louis, MO
North Carolina · 2
- University of North Carolina at Chapel Hill · Chapel Hill, NC
- Duke University Medical Center · Durham, NC
Oklahoma · 1
- Sarah Cannon Research Institute University of Oklahoma · Oklahoma City, OK
Oregon · 1
- Providence Portland Medical Center · Portland, OR
Texas · 1
- Mays Cancer Center / University of Texas, San Antonio · San Antonio, TX
Virginia · 1
- NEXT Virginia · Fairfax, VA
Washington · 1
- Fred Hutch Cancer Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.